In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.87% at $2.89. This change lagged the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.59%, and the tech-heavy ...

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.34, demonstrating a +1.21% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.38%.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...